Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment [PDF]
Scientific ReportsWe evaluated the incidence and risk factors for recurrence in patients with neovascular age-related macular degeneration (nAMD) who discontinued anti-vascular endothelial growth factor (VEGF) therapy under a modified treat-and-extend (TAE) protocol.
Junwoo Lee +3 more
doaj +2 more sources
Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy [PDF]
Ophthalmology and Therapy, 2023 Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical ...
Chu-Hsuan Huang +3 more
doaj +2 more sources
A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration [PDF]
Frontiers in Medicine, 2022 PurposeTo compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD).MethodsThis was a randomized, multicenter, non-
Huixun Jia +22 more
doaj +2 more sources
Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up [PDF]
Clinical OphthalmologyTaras B Kustryn, Oleg S Zadorozhnyy, Illia O Nasinnyk, Alla O Nevska, Kseniia V Troianovska, Nataliya V Pasyechnikova, Andrii R Korol Laser Microsurgery Department, The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of ...
Kustryn TB +6 more
doaj +2 more sources
Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel. [PDF]
Eye (Lond), 2023 Bailey C +10 more
europepmc +3 more sources
Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE). [PDF]
Eye (Lond)Wijesingha N +3 more
europepmc +3 more sources
One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema. [PDF]
J Chin Med Assoc, 2022 Sheu SJ +4 more
europepmc +2 more sources
The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol [PDF]
International Ophthalmology, 2021 To investigate the adherence rate of neovascular age-related macular degeneration (nAMD) patients in treat-and-extend (TAE) protocol to their anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection (IVI) appointments and to evaluate the functional and anatomical outcomes of the patients who attended and did not attend their IVI ...
Mehmet Orkun Sevik +4 more
openaire +3 more sources
Frontiers in Medicine, 2021 The use of anti-vascular-endothelial growth factor agents for neovascular age-related macular degeneration (nAMD) in different treatment schemes is widely common in clinical practice.
Laura Hoffmann, Katja Hatz, Katja Hatz
doaj +1 more source
Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema [PDF]
Scientific Reports, 2020 AbstractThis study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment.
Yu Cheol Kim +8 more
openaire +3 more sources